Hjem › Nyrekreft (nyrecellekarcinom) › North Carolina › Durham
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Durham, NC
12 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i og rundt Durham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
RekruttererFase 1/2
- Duke Cancer Institute ( Site 5015), Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Durham VA Medical Center, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #12, Durham
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruttererFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
DESTINY-PANTUMOUR04
RekruttererObservasjonsstudie
- Research Site, Durham
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekruttererFase 2
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruttererObservasjonsstudie
- UNC- Chapel Hill, Chapel Hill · 10 mi unna
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
RekruttererFase 2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RekruttererFase 3
- Duke University Medical Center, Durham
- Duke Cancer Center Southpoint, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi unna
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekruttererFase 1
- Duke Cancer Center /ID# 251975, Durham
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RekruttererFase 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi unna
Nyrekreft (nyrecellekarcinom)-studier i andre byer
- Houston, TX35 studier
- New York City, NY27 studier
- Nashville, TN23 studier
- Dallas, TX23 studier
- St. Louis, MO23 studier
- Los Angeles, CA20 studier
- Boston, MA16 studier
- Baldwin Park, CA16 studier
- Philadelphia, PA15 studier
- Pittsburgh, PA15 studier
- Queens, NY15 studier
- Rochester, MN14 studier
Andre studier i Durham
- Brystkreft64 studier
- Kreft (alle typer)58 studier
- Ikke-småcellet lungekreft39 studier
- Multipelt myelom37 studier
- Akut myelogen leukemi33 studier
- Metastatisk kreft33 studier
- Prostatakreft32 studier
- Lungekreft32 studier
- Kolorektal kreft28 studier
- Eggstokkreft27 studier
- Kronisk lymfatisk leukemi27 studier
- Hjertesvikt26 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.